Tempest Therapeutics (TPST) Enterprise Value (2012 - 2026)

Tempest Therapeutics has disclosed Enterprise Value across 15 years of filings, most recently posting $4.7 million for Q2 2026.

• In Q2 2026, Enterprise Value fell 70.59% year-over-year to $4.7 million; the TTM figure through Jun 2026 stood at $4.7 million (down 70.59% YoY), while the FY2025 annual figure was $6.4 million, up 192.15% from the prior year.
• Enterprise Value came in at $4.7 million for Q2 2026 at Tempest Therapeutics, down from $6.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $54.5 million in Q1 2024 to a low of -$44.4 million in Q2 2022.
• Average Enterprise Value over 5 years is $3.3 million, with a median of $6.4 million recorded in 2025.
• Year-over-year, Enterprise Value sank 185.18% in 2022 and surged 1484.68% in 2024.
• Over 5 years, Enterprise Value stood at -$19.6 million in 2022, then soared by 246.03% to $28.6 million in 2023, then sank by 124.41% to -$7.0 million in 2024, then surged by 192.15% to $6.4 million in 2025, then decreased by 27.43% to $4.7 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $4.7 million in Q2 2026, $6.4 million in Q4 2025, and $38.1 million in Q3 2025.